• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用甲基阅读蛋白进行细胞核特异性蛋白质降解

Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation.

作者信息

Nalawansha Dhanusha A, Li Ke, Hines John, Crews Craig M

机构信息

Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06511, United States.

Department of Chemistry, Yale University, New Haven, Connecticut 06511, United States.

出版信息

J Am Chem Soc. 2022 Mar 30;144(12):5594-5605. doi: 10.1021/jacs.2c00874. Epub 2022 Mar 21.

DOI:10.1021/jacs.2c00874
PMID:35311258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10331457/
Abstract

Targeted protein degradation (TPD) by PROTACs is a promising strategy to control disease-causing protein levels within the cell. While TPD is emerging as an innovative drug discovery paradigm, there are currently only a limited number of E3 ligase:ligand pairs that are employed to induce protein degradation. Herein, we report a novel approach to induce protein degradation by hijacking a methyl reader:E3 ligase complex. L3MBTL3 is a methyl-lysine reader protein that binds to the Cul4 E3 ligase complex and targets methylated proteins for proteasomal degradation. By co-opting this natural mechanism, we report the design and biological evaluation of L3MBTL3-recruiting PROTACs and demonstrate nuclear-specific degradation of FKBP12 and BRD2. We envision this as a generalizable approach to utilize other reader protein-associated E3 ligase complexes in PROTAC design to expand the E3 ligase toolbox and explore the full potential of TPD.

摘要

通过PROTAC进行靶向蛋白质降解(TPD)是一种控制细胞内致病蛋白水平的有前景的策略。虽然TPD正在成为一种创新的药物发现范式,但目前用于诱导蛋白质降解的E3连接酶:配体对数量有限。在此,我们报告了一种通过劫持甲基阅读器:E3连接酶复合物来诱导蛋白质降解的新方法。L3MBTL3是一种甲基赖氨酸阅读器蛋白,它与Cul4 E3连接酶复合物结合,并将甲基化蛋白靶向蛋白酶体降解。通过利用这种天然机制,我们报告了招募L3MBTL3的PROTAC的设计和生物学评估,并证明了FKBP12和BRD2的核特异性降解。我们设想这是一种通用方法,可在PROTAC设计中利用其他与阅读器蛋白相关的E3连接酶复合物来扩展E3连接酶工具箱并探索TPD的全部潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/aa2265912f47/nihms-1912250-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/3491721cddce/nihms-1912250-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/d4fa8be3cfe7/nihms-1912250-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/3c95f01cc8b3/nihms-1912250-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/096f79f60cff/nihms-1912250-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/2c61f5d5a3bc/nihms-1912250-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/aa2265912f47/nihms-1912250-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/3491721cddce/nihms-1912250-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/d4fa8be3cfe7/nihms-1912250-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/3c95f01cc8b3/nihms-1912250-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/096f79f60cff/nihms-1912250-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/2c61f5d5a3bc/nihms-1912250-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/686e/10331457/aa2265912f47/nihms-1912250-f0007.jpg

相似文献

1
Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation.利用甲基阅读蛋白进行细胞核特异性蛋白质降解
J Am Chem Soc. 2022 Mar 30;144(12):5594-5605. doi: 10.1021/jacs.2c00874. Epub 2022 Mar 21.
2
Discovery of E3 Ligase Ligands for Target Protein Degradation.E3 连接酶配体用于靶蛋白降解的发现。
Molecules. 2022 Oct 2;27(19):6515. doi: 10.3390/molecules27196515.
3
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.PROTACs:药物发现中蛋白质降解的新兴靶向技术。
Bioessays. 2018 Apr;40(4):e1700247. doi: 10.1002/bies.201700247. Epub 2018 Feb 23.
4
Proteolysis of methylated SOX2 protein is regulated by L3MBTL3 and CRL4 ubiquitin ligase.组蛋白甲基化 SOX2 蛋白的蛋白水解受到 L3MBTL3 和 CRL4 泛素连接酶的调控。
J Biol Chem. 2019 Jan 11;294(2):476-489. doi: 10.1074/jbc.RA118.005336. Epub 2018 Nov 15.
5
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules.小分子通过 KLHDC2 E3 连接酶实现靶向蛋白降解。
Nat Struct Mol Biol. 2024 Feb;31(2):311-322. doi: 10.1038/s41594-023-01146-w. Epub 2024 Jan 4.
6
Fragment-based approaches to discover ligands for tumor-specific E3 ligases.基于片段的方法发现肿瘤特异性E3连接酶的配体。
Expert Opin Drug Discov. 2024 Dec;19(12):1471-1484. doi: 10.1080/17460441.2024.2415310. Epub 2024 Oct 17.
7
Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders.优化针对 E3 连接酶 DCAF15 的有效配体,并评估其在杂双功能降解剂中的应用。
J Med Chem. 2024 Apr 11;67(7):5538-5566. doi: 10.1021/acs.jmedchem.3c02136. Epub 2024 Mar 21.
8
A synthetic KLHL20 ligand to validate CUL3 as a potent E3 ligase for targeted protein degradation.一种合成的 KLHL20 配体,用于验证 CUL3 作为一种有效的 E3 连接酶,用于靶向蛋白质降解。
Genes Dev. 2022 Sep 1;36(17-18):1031-1042. doi: 10.1101/gad.349717.122. Epub 2022 Nov 3.
9
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution.靶向蛋白降解:E3 连接酶解析的当前和新兴方法。
J Med Chem. 2024 Jul 25;67(14):11580-11596. doi: 10.1021/acs.jmedchem.4c00723. Epub 2024 Jul 9.
10
PROTACs: A novel strategy for cancer drug discovery and development.PROTACs:癌症药物发现与开发的新策略。
MedComm (2020). 2023 May 29;4(3):e290. doi: 10.1002/mco2.290. eCollection 2023 Jun.

引用本文的文献

1
E3Docker: a docking server for potential E3 binder discovery.E3Docker:用于发现潜在E3结合剂的对接服务器。
Nucleic Acids Res. 2025 May 8. doi: 10.1093/nar/gkaf391.
2
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.通过桥接蛋白酶靶向嵌合体(PROTAC)策略利用SPOP E3泛素连接酶进行靶向蛋白降解。
J Med Chem. 2025 Apr 24;68(8):8634-8647. doi: 10.1021/acs.jmedchem.5c00295. Epub 2025 Apr 9.
3
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions.

本文引用的文献

1
Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications.发现一种用于靶向蛋白降解应用的共价 FEM1B 招募剂。
J Am Chem Soc. 2022 Jan 19;144(2):701-708. doi: 10.1021/jacs.1c03980. Epub 2022 Jan 7.
2
The nuclear transcription factor, TAF7, is a cytoplasmic regulator of protein synthesis.核转录因子TAF7是蛋白质合成的细胞质调节剂。
Sci Adv. 2021 Dec 10;7(50):eabi5751. doi: 10.1126/sciadv.abi5751.
3
Ligandability of E3 Ligases for Targeted Protein Degradation Applications.E3 连接酶的配体化在靶向蛋白降解应用中的研究进展。
癌症治疗中的蛋白质降解靶向嵌合体:作用机制、设计、临床试验及未来方向。
Drug Deliv Transl Res. 2025 Jun;15(6):1801-1827. doi: 10.1007/s13346-024-01754-z. Epub 2024 Nov 29.
4
Targeted protein degradation: advances in drug discovery and clinical practice.靶向蛋白降解:药物发现和临床实践的进展。
Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.
5
Development of PROTACS degrading KRAS and SOS1.开发降解 KRAS 和 SOS1 的 PROTACS。
Oncol Res. 2024 Jul 17;32(8):1257-1264. doi: 10.32604/or.2024.051653. eCollection 2024.
6
Lysine Methylation-Dependent Proteolysis by the Malignant Brain Tumor (MBT) Domain Proteins.赖氨酸甲基化依赖性蛋白水解作用由恶性脑肿瘤(MBT)结构域蛋白介导。
Int J Mol Sci. 2024 Feb 13;25(4):2248. doi: 10.3390/ijms25042248.
7
DNA framework-engineered chimeras platform enables selectively targeted protein degradation.DNA 框架工程嵌合体平台实现了选择性靶向蛋白降解。
Nat Commun. 2023 Jul 27;14(1):4510. doi: 10.1038/s41467-023-40244-7.
8
PROTACs: A novel strategy for cancer drug discovery and development.PROTACs:癌症药物发现与开发的新策略。
MedComm (2020). 2023 May 29;4(3):e290. doi: 10.1002/mco2.290. eCollection 2023 Jun.
9
Chemical tools targeting readers of lysine methylation.靶向赖氨酸甲基化读者的化学工具。
Curr Opin Chem Biol. 2023 Jun;74:102286. doi: 10.1016/j.cbpa.2023.102286. Epub 2023 Mar 20.
10
Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1.通过立体选择性和位点特异性结合 DCAF1 的亲电 PROTAC 实现靶向蛋白降解。
J Am Chem Soc. 2022 Oct 12;144(40):18688-18699. doi: 10.1021/jacs.2c08964. Epub 2022 Sep 28.
Biochemistry. 2023 Feb 7;62(3):588-600. doi: 10.1021/acs.biochem.1c00464. Epub 2021 Sep 2.
4
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.靶向蛋白降解嵌合体(PROTACs)步入成熟:进入靶向蛋白降解的第三个十年。
RSC Chem Biol. 2021 Mar 19;2(3):725-742. doi: 10.1039/d1cb00011j.
5
Targeted protein degradation: A promise for undruggable proteins.靶向蛋白降解:不可成药蛋白的新希望。
Cell Chem Biol. 2021 Jul 15;28(7):934-951. doi: 10.1016/j.chembiol.2021.04.011. Epub 2021 May 17.
6
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.拓展 E3 泛素连接酶的武器库以实现邻近诱导的蛋白质降解。
Cell Chem Biol. 2021 Jul 15;28(7):1014-1031. doi: 10.1016/j.chembiol.2021.04.007. Epub 2021 May 3.
7
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.一种 E3 连接酶引导的小分子诱导蛋白降解的星系。
Cell Chem Biol. 2021 Jul 15;28(7):1000-1013. doi: 10.1016/j.chembiol.2021.04.002. Epub 2021 Apr 22.
8
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.DCAF11 通过亲电蛋白水解靶向嵌合体支持靶向蛋白降解。
J Am Chem Soc. 2021 Apr 7;143(13):5141-5149. doi: 10.1021/jacs.1c00990. Epub 2021 Mar 30.
9
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
10
Bardoxolone conjugation enables targeted protein degradation of BRD4.巴多索隆缀合能够实现 BRD4 的靶向蛋白降解。
Sci Rep. 2020 Sep 23;10(1):15543. doi: 10.1038/s41598-020-72491-9.